Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection

Standard

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. / von Felden, Johann; Schulze, Kornelius; Krech, Till; Ewald, Florian; Nashan, Björn; Pantel, Klaus; Lohse, Ansgar W; Riethdorf, Sabine; Wege, Henning.

in: ONCOTARGET, Jahrgang 8, Nr. 52, 27.10.2017, S. 89978-89987.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{8699e12faa024d42950201e7e0fd2b08,
title = "Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection",
abstract = "Background: Early hepatocellular carcinoma (HCC) has a limited prognosis due to recurrence rates of more than 50% after liver resection. Recurrence within two years is believed to be caused by untraceable micro metastases at the time of resection. The objective of this study was to investigate EpCAM-positive circulating tumor cells (CTC) as liquid biomarker to identify patients with high risk of recurrence after liver resection.Methods: 61 patients undergoing resection between 2011 and 2015 were consecutively enrolled. Blood specimens were obtained prior to surgery and processed with the CellSearchTM system, detecting EpCAM-positive CTC. The primary endpoint was recurrence-free survival (RFS).Results: 13 women and 44 men (63.6 ± 11.1 years) were finally evaluated. CTC-positive patients had a significantly higher risk of recurrence with a hazard ratio (HR) of 2.3 (p=0.027), and a shorter RFS compared to CTC-negative patients (5.0 ± 1.5 vs. 12.0 ± 2.5 months, p=0.039). As expected, incomplete resection (R1) was also associated with shorter RFS (HR=2.6, p=0.035), but vascular invasion was not. However, the predictive power of CTC status was independent of R1.Conclusion: Bloodstream detection of CTC prior to curative-intended liver resection discloses an elevated risk of HCC recurrence and could identify patients, who might benefit from adjuvant treatment.",
keywords = "Journal Article",
author = "{von Felden}, Johann and Kornelius Schulze and Till Krech and Florian Ewald and Bj{\"o}rn Nashan and Klaus Pantel and Lohse, {Ansgar W} and Sabine Riethdorf and Henning Wege",
year = "2017",
month = oct,
day = "27",
doi = "10.18632/oncotarget.21208",
language = "English",
volume = "8",
pages = "89978--89987",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "52",

}

RIS

TY - JOUR

T1 - Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection

AU - von Felden, Johann

AU - Schulze, Kornelius

AU - Krech, Till

AU - Ewald, Florian

AU - Nashan, Björn

AU - Pantel, Klaus

AU - Lohse, Ansgar W

AU - Riethdorf, Sabine

AU - Wege, Henning

PY - 2017/10/27

Y1 - 2017/10/27

N2 - Background: Early hepatocellular carcinoma (HCC) has a limited prognosis due to recurrence rates of more than 50% after liver resection. Recurrence within two years is believed to be caused by untraceable micro metastases at the time of resection. The objective of this study was to investigate EpCAM-positive circulating tumor cells (CTC) as liquid biomarker to identify patients with high risk of recurrence after liver resection.Methods: 61 patients undergoing resection between 2011 and 2015 were consecutively enrolled. Blood specimens were obtained prior to surgery and processed with the CellSearchTM system, detecting EpCAM-positive CTC. The primary endpoint was recurrence-free survival (RFS).Results: 13 women and 44 men (63.6 ± 11.1 years) were finally evaluated. CTC-positive patients had a significantly higher risk of recurrence with a hazard ratio (HR) of 2.3 (p=0.027), and a shorter RFS compared to CTC-negative patients (5.0 ± 1.5 vs. 12.0 ± 2.5 months, p=0.039). As expected, incomplete resection (R1) was also associated with shorter RFS (HR=2.6, p=0.035), but vascular invasion was not. However, the predictive power of CTC status was independent of R1.Conclusion: Bloodstream detection of CTC prior to curative-intended liver resection discloses an elevated risk of HCC recurrence and could identify patients, who might benefit from adjuvant treatment.

AB - Background: Early hepatocellular carcinoma (HCC) has a limited prognosis due to recurrence rates of more than 50% after liver resection. Recurrence within two years is believed to be caused by untraceable micro metastases at the time of resection. The objective of this study was to investigate EpCAM-positive circulating tumor cells (CTC) as liquid biomarker to identify patients with high risk of recurrence after liver resection.Methods: 61 patients undergoing resection between 2011 and 2015 were consecutively enrolled. Blood specimens were obtained prior to surgery and processed with the CellSearchTM system, detecting EpCAM-positive CTC. The primary endpoint was recurrence-free survival (RFS).Results: 13 women and 44 men (63.6 ± 11.1 years) were finally evaluated. CTC-positive patients had a significantly higher risk of recurrence with a hazard ratio (HR) of 2.3 (p=0.027), and a shorter RFS compared to CTC-negative patients (5.0 ± 1.5 vs. 12.0 ± 2.5 months, p=0.039). As expected, incomplete resection (R1) was also associated with shorter RFS (HR=2.6, p=0.035), but vascular invasion was not. However, the predictive power of CTC status was independent of R1.Conclusion: Bloodstream detection of CTC prior to curative-intended liver resection discloses an elevated risk of HCC recurrence and could identify patients, who might benefit from adjuvant treatment.

KW - Journal Article

U2 - 10.18632/oncotarget.21208

DO - 10.18632/oncotarget.21208

M3 - SCORING: Journal articles

C2 - 29163804

VL - 8

SP - 89978

EP - 89987

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 52

ER -